Ovary, Phase II

A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.

Trial with
Cybrexa 2, Inc.
Ages
18 years - 99 years
Gender
Female only

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Elena Ratner

elena.ratner@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Elena Ratner, MD, MBA
Professor of Obstetrics, Gynecology & Reproductive Sciences; Co-Chief, Section of Gynecologic Oncology

Sub-Investigators

Last Updated
12/26/2024
Study HIC
#2000038140